Efficacy of danhong injection adjuvant therapy in patients with acute ischemic stroke: a real-world, multicenter, retrospective study
BackgroundPrevious clinical and experimental studies indicate that Danhong injection (DHI) confers protective effects against acute ischemic stroke (AIS). However, due to limited sample sizes, large-scale clinical studies are still needed to confirm its efficacy.MethodsThis real-world, multicenter r...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1608719/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850129400559828992 |
|---|---|
| author | Danping Pan Haitong Wan Haitong Wan Yu He Jiehong Yang Yilei Guo Li Yu Feihu Zhang Guoqing Zheng Bin Xu Yaohong Song Mingjun Zhao Xiangzhe Liu Jianhe Liu Gang Sun Yaming Lin |
| author_facet | Danping Pan Haitong Wan Haitong Wan Yu He Jiehong Yang Yilei Guo Li Yu Feihu Zhang Guoqing Zheng Bin Xu Yaohong Song Mingjun Zhao Xiangzhe Liu Jianhe Liu Gang Sun Yaming Lin |
| author_sort | Danping Pan |
| collection | DOAJ |
| description | BackgroundPrevious clinical and experimental studies indicate that Danhong injection (DHI) confers protective effects against acute ischemic stroke (AIS). However, due to limited sample sizes, large-scale clinical studies are still needed to confirm its efficacy.MethodsThis real-world, multicenter retrospective study used inpatient data from eight centers across Mainland China. AIS patients were divided into a DHI group or a Non-DHI group depending on whether they received DHI (7–14 consecutive days). Propensity score matching (PSM) was applied to balance baseline differences, and multiple analytical methods (crude analysis, multivariate regression, stabilized inverse probability of treatment weighting [sIPTW], and PSM combined with multivariate regression) were conducted. The primary outcome was the NIHSS score at discharge. Secondary outcomes included the proportions of patients with post-treatment NIHSS scores ≤4 or ≤1, the mRS score, the proportion of patients achieving mRS ≤1, and the incidence of in-hospital complications (IHC).ResultsA total of 3,560 patients were enrolled, including 1,425 in the DHI group, and 2,135 in the Non-DHI group, with 1,415 matched pairs identified via PSM. After treatment, the NIHSS score in the DHI group was 2.01 ± 3.10, compared with 2.50 ± 3.26 in the Non-DHI group, indicating significantly lower scores in the DHI group (adjusted RR = 0.81, 95% CI: 0.74–0.88, P < 0.001). These findings were consistent across multiple analytical methods (RR = 0.79–0.82). After treatment, the proportion of patients with NIHSS ≤4 and ≤1 was higher in the DHI group (adjusted RR = 1.02, 95% CI: 1.01–1.03, P = 0.005; adjusted RR = 1.07, 95% CI: 1.05–1.10, P < 0.001). The DHI group also had a lower mRS score (P < 0.001) and a higher proportion of patients achieving mRS ≤1 (adjusted RR = 1.12, 95% CI: 1.10–1.15, P < 0.001). No noteworthy difference was found between the two groups in the incidence of IHC (adjusted RR = 1.01, 95% CI: 0.99–1.03, P = 0.320).ConclusionDHI adjunctive therapy may improve neurological outcomes in patients with AIS. However, additional randomized controlled trials (RCTs) are needed to confirm its effectiveness in routine biomedicine-based clinical practice.Clinical Trial Registrationhttps://www.chictr.org.cn/bin/project/edit?pid=211769, identifier ChiCTR2400079391. |
| format | Article |
| id | doaj-art-e11df09ee5a5469fbbcbe1e7c74ed764 |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-e11df09ee5a5469fbbcbe1e7c74ed7642025-08-20T02:33:00ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-06-011610.3389/fphar.2025.16087191608719Efficacy of danhong injection adjuvant therapy in patients with acute ischemic stroke: a real-world, multicenter, retrospective studyDanping Pan0Haitong Wan1Haitong Wan2Yu He3Jiehong Yang4Yilei Guo5Li Yu6Feihu Zhang7Guoqing Zheng8Bin Xu9Yaohong Song10Mingjun Zhao11Xiangzhe Liu12Jianhe Liu13Gang Sun14Yaming Lin15School of Basic Mecicine Sciences, Zhejiang Chinese Medical University, Hangzhou, ChinaSchool of Basic Mecicine Sciences, Zhejiang Chinese Medical University, Hangzhou, ChinaAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, ChinaSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, ChinaSchool of Basic Mecicine Sciences, Zhejiang Chinese Medical University, Hangzhou, ChinaSchool of Basic Mecicine Sciences, Zhejiang Chinese Medical University, Hangzhou, ChinaSchool of Basic Mecicine Sciences, Zhejiang Chinese Medical University, Hangzhou, ChinaSchool of Basic Mecicine Sciences, Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, ChinaDepartment of Neurology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Cardiology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Cardiology, Affliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, ChinaDepartment of Encephalology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, ChinaDepartment of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, China0Department of Cardiology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China1Department of Neurology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, ChinaBackgroundPrevious clinical and experimental studies indicate that Danhong injection (DHI) confers protective effects against acute ischemic stroke (AIS). However, due to limited sample sizes, large-scale clinical studies are still needed to confirm its efficacy.MethodsThis real-world, multicenter retrospective study used inpatient data from eight centers across Mainland China. AIS patients were divided into a DHI group or a Non-DHI group depending on whether they received DHI (7–14 consecutive days). Propensity score matching (PSM) was applied to balance baseline differences, and multiple analytical methods (crude analysis, multivariate regression, stabilized inverse probability of treatment weighting [sIPTW], and PSM combined with multivariate regression) were conducted. The primary outcome was the NIHSS score at discharge. Secondary outcomes included the proportions of patients with post-treatment NIHSS scores ≤4 or ≤1, the mRS score, the proportion of patients achieving mRS ≤1, and the incidence of in-hospital complications (IHC).ResultsA total of 3,560 patients were enrolled, including 1,425 in the DHI group, and 2,135 in the Non-DHI group, with 1,415 matched pairs identified via PSM. After treatment, the NIHSS score in the DHI group was 2.01 ± 3.10, compared with 2.50 ± 3.26 in the Non-DHI group, indicating significantly lower scores in the DHI group (adjusted RR = 0.81, 95% CI: 0.74–0.88, P < 0.001). These findings were consistent across multiple analytical methods (RR = 0.79–0.82). After treatment, the proportion of patients with NIHSS ≤4 and ≤1 was higher in the DHI group (adjusted RR = 1.02, 95% CI: 1.01–1.03, P = 0.005; adjusted RR = 1.07, 95% CI: 1.05–1.10, P < 0.001). The DHI group also had a lower mRS score (P < 0.001) and a higher proportion of patients achieving mRS ≤1 (adjusted RR = 1.12, 95% CI: 1.10–1.15, P < 0.001). No noteworthy difference was found between the two groups in the incidence of IHC (adjusted RR = 1.01, 95% CI: 0.99–1.03, P = 0.320).ConclusionDHI adjunctive therapy may improve neurological outcomes in patients with AIS. However, additional randomized controlled trials (RCTs) are needed to confirm its effectiveness in routine biomedicine-based clinical practice.Clinical Trial Registrationhttps://www.chictr.org.cn/bin/project/edit?pid=211769, identifier ChiCTR2400079391.https://www.frontiersin.org/articles/10.3389/fphar.2025.1608719/fulldanhong injectionacute ischemic strokeclinical efficacyreal-world multicenter retrospective studytraditional Chinese medicine |
| spellingShingle | Danping Pan Haitong Wan Haitong Wan Yu He Jiehong Yang Yilei Guo Li Yu Feihu Zhang Guoqing Zheng Bin Xu Yaohong Song Mingjun Zhao Xiangzhe Liu Jianhe Liu Gang Sun Yaming Lin Efficacy of danhong injection adjuvant therapy in patients with acute ischemic stroke: a real-world, multicenter, retrospective study Frontiers in Pharmacology danhong injection acute ischemic stroke clinical efficacy real-world multicenter retrospective study traditional Chinese medicine |
| title | Efficacy of danhong injection adjuvant therapy in patients with acute ischemic stroke: a real-world, multicenter, retrospective study |
| title_full | Efficacy of danhong injection adjuvant therapy in patients with acute ischemic stroke: a real-world, multicenter, retrospective study |
| title_fullStr | Efficacy of danhong injection adjuvant therapy in patients with acute ischemic stroke: a real-world, multicenter, retrospective study |
| title_full_unstemmed | Efficacy of danhong injection adjuvant therapy in patients with acute ischemic stroke: a real-world, multicenter, retrospective study |
| title_short | Efficacy of danhong injection adjuvant therapy in patients with acute ischemic stroke: a real-world, multicenter, retrospective study |
| title_sort | efficacy of danhong injection adjuvant therapy in patients with acute ischemic stroke a real world multicenter retrospective study |
| topic | danhong injection acute ischemic stroke clinical efficacy real-world multicenter retrospective study traditional Chinese medicine |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1608719/full |
| work_keys_str_mv | AT danpingpan efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT haitongwan efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT haitongwan efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT yuhe efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT jiehongyang efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT yileiguo efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT liyu efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT feihuzhang efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT guoqingzheng efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT binxu efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT yaohongsong efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT mingjunzhao efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT xiangzheliu efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT jianheliu efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT gangsun efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy AT yaminglin efficacyofdanhonginjectionadjuvanttherapyinpatientswithacuteischemicstrokearealworldmulticenterretrospectivestudy |